<DOC>
	<DOCNO>NCT00679510</DOCNO>
	<brief_summary>Patients rheumatoid arthritis increase risk cardiovascular death . Our study aim look effect prove cholesterol lower treatment drug call rosuvastatin rheumatoid arthritis patient cardiovascular marker . Endothelial behaviour improve treatment .</brief_summary>
	<brief_title>Rosuvastatin Rheumatoid Arthritis ( RORA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Patients select high risk population hospital clinic attendee , define RA great 5 year ' disease duration , RA latex seropositive IgM RF ELISA &gt; 14iu/ml . The subject either sex &gt; 40 year age . Patients tender swell joint count &gt; 4 either CRP &gt; 10mg/l , ESR &gt; 25mm/h PV &gt; 1.78 . Patients cyclosporine medication know contraindicated form drug enrol . The patient 's hospital general practice record scrutinise evidence symptomatic vascular disease . Any patient free vascular disease symptom exclude . In addition evidence symptomatic vascular disease ( either previous current ) , exclusion criterion consist also already take lipidlowering therapy contraindication therapy . Also exclude subject total cholesterol level &gt; 7.5mmol/L might argue patient merit primary prevention basis dyslipidemia alone .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Rosuvastatin</keyword>
	<keyword>Cardiovascular</keyword>
	<keyword>Intima medium thickness</keyword>
</DOC>